ELISA Kit for Lysophosphatidylcholine (LPC)

Format

48T, 96T, 96T×5, 96T×10, 96T×100

Detection range

246.9-20,000ng/mL

Application

Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species

Pan-species (General)

Sensitivity

The minimum detectable dose of this kit is typically less than 92.4ng/mL

Sample type

Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids

Assay length

2h

Method

Competitive Inhibition

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Lysophosphatidylcholine (LPC) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Lysophosphatidylcholine (LPC) and unlabeled Lysophosphatidylcholine (LPC) (Standards or samples) with the pre-coated antibody specific to Lysophosphatidylcholine (LPC). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Lysophosphatidylcholine (LPC) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Lysophosphatidylcholine (LPC) in the sample.

Alternative Names

lysoPC; Lysolecithin; 1-Palmitoyl-sn-Glycero-3-Phosphocholine

Item Name

Lysophosphatidylcholine

Research Area

Reference

High-fat diet-induced acceleration of osteoarthritis is associated with a distinct and sustained plasma metabolite signature;Iron Homeostasis Determines Fate of Human Pluripotent Stem Cells Via Glycerophospholipids‐Epigenetic Circuit;Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy;ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy;